24小时热门版块排行榜    

Znn3bq.jpeg
查看: 566  |  回复: 3

984208320

木虫 (正式写手)

[交流] 【Share】Malaria: New Partnership Aims to Stop Parasite in its Tracks

A new partnership is being launched to develop a malaria vaccine that would prevent parasites from entering the liver. Most of the symptoms of the disease develop after parasites have had time to replicate there.

The World Health Organization estimates that in 2008, there were 247 million cases of malaria worldwide, with one million deaths. It says in Africa, a child dies every 45 seconds from the disease.

The best treatment now available is artemisinin-based combination therapy. But an effective vaccine would be much better. That's the goal of the partnership involving the international, non-profit organization PATH, Merck Pharmaceuticals and New York University.

Finding a weakness

Scientists think they've discovered the Achilles heel of the malaria parasite. After a bite by an infected mosquito, the parasite travels through the bloodstream and arrives at the liver. That's where scientists believe the best line of defense can be made.

Dr. Ashley Birkett is PATH's Malaria Vaccine Initiative director of pre and early clinical development.

"The parasite has a natural affinity for liver cells. Liver cells are the cells that the parasite can actually make copies of itself in once it enters the human body. So, it's goal once it enters the human bloodstream after an infectious bite is to find liver cells. And then it enters those liver cells through a set of specific interactions that we don't fully understand. But there is a critical event in that entry process that we think we can target through a vaccine approach," he says.

He says if the parasite cannot enter the liver, it cannot replicate and cause disease. But targeting a parasite is more difficult than targeting viruses or bacteria.

"This is a parasite," he says, "It's a very complex organism that has over 5,000 different gene products that it makes. It's a lot more complicated than a typical virus. I think also there have been limited resources that have been applied to malaria vaccine development over the years. But we are having significant success now. And through a partnership with GlaxoSmithKline, PATH MVI is engaged in a very large phase-three clinical study, which is a last stage of clinical testing before a vaccine can actually be licensed and start saving lives."

Birkett says the vaccine has been evaluated in 16,000 young children in seven sub-Saharan African countries. It has an efficacy rate of 50 percent.

"So, given that we're looking in the order of 900,000 deaths from malaria in young children primarily per year in sub-Saharan Africa, a vaccine with 50 percent efficacy is actually a very significant achievement. But we want to do better," says Birkett.

The vaccine being tested depends on the body producing very large numbers of antibodies against the malaria parasite. That's makes it more difficult to have a higher efficacy rate. The hope of a new vaccine is to specifically target a different area of the parasite with fewer anti-bodies.

Malaria taking a toll

Dr. Birkett says this would relieve African countries of some heavy burdens.

"We're looking at countries in sub-Saharan Africa, which already have significant burdens to deal with in terms of economic impact of these global infectious diseases. And malaria has a huge economic impact. So a vaccine that can be highly protective and prevent these clinical diseases and up to 900,000 deaths per year is going to have a significant health and economic benefit in these countries," he says.

Dr. Birkett says the cost of such a vaccine would be kept as low as possible. Clinical testing on the proposed vaccine is still three or four years away. Malaria immunization would be included as part of a child's routine vaccinations.
回复此楼
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

小木虫(沙发+1,金币+0.5):恭喜抢个沙发,再给个红包
2楼2010-12-15 10:24:20
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

小木虫(金币+0.2):抢了个小板凳,给个红包
3楼2010-12-15 10:24:21
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
4楼2010-12-15 21:35:27
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
相关版块跳转 我要订阅楼主 984208320 的主题更新
普通表情 高级回复 (可上传附件)
最具人气热帖推荐 [查看全部] 作者 回/看 最后发表
[基金申请] 国自然面上和省基金B类撒花 +8 花田半亩~白 2026-04-21 8/400 2026-04-22 14:59 by jiaoxg
[考博] 华师大读博 +3 xq83 2026-04-22 5/250 2026-04-22 10:42 by xq83
[考研] 0854求调剂 +24 门路摸摸 2026-04-15 28/1400 2026-04-22 09:54 by Sy199704!
[论文投稿] 急需审稿人!!! +3 陆小果画大饼 2026-04-21 3/150 2026-04-21 23:54 by jzy_123456
[考研] 一志愿中科大材料与化工,353分还有调剂学校吗 +11 否极泰来2026 2026-04-15 13/650 2026-04-20 22:31 by Equinoxhua
[考研] 085600材料与化工调剂 5+3 孜孜不倦2002 2026-04-19 6/300 2026-04-20 21:25 by babero
[论文投稿] 有没有接收比较快的sci期刊呀,最好在一个月之内的,研三孩子求毕业 20+4 之护着 2026-04-16 7/350 2026-04-20 15:45 by 豆豆7758
[考研] 337求调剂 +3 jyz04 2026-04-18 3/150 2026-04-20 12:24 by 研可安
[考博] 申博 +3 Xyyx. 2026-04-18 3/150 2026-04-20 10:44 by YuY66
[考博] 湖南大学刘巧玲课题组2026年第二批次博士研究生招生信息 +3 南风观火 2026-04-18 5/250 2026-04-20 10:13 by 南风观火
[考研] 294求调剂 +8 淡然654321 2026-04-17 9/450 2026-04-19 19:51 by Equinoxhua
[考研] 304求调剂 +8 castLight 2026-04-16 8/400 2026-04-19 17:14 by 中豫男
[考研] 求调剂 +6 苦命人。。。 2026-04-18 7/350 2026-04-19 16:27 by 中豫男
[考研] 300求调剂 +12 橙a777 2026-04-15 12/600 2026-04-18 23:51 by 路病情
[考研] 接受任何调剂 +6 也就是栗子 2026-04-17 7/350 2026-04-18 17:20 by 涵竹刘
[考研] 收到复试调剂但是去不了 +8 小蜗牛* 2026-04-16 8/400 2026-04-18 11:15 by zixin2025
[考研] 260求调剂 +4 Zyt1314520.. 2026-04-17 5/250 2026-04-18 08:28 by babysonlkd
[考研] 急需调剂 +9 绝不放弃22 2026-04-15 10/500 2026-04-18 08:09 by chixmc
[有机交流] 二苯甲酮酸类衍生物 50+3 小白爱主人 2026-04-17 6/300 2026-04-17 18:47 by kf2781974
[考研] 322求调剂 +6 tekuzu 2026-04-17 6/300 2026-04-17 13:48 by Espannnnnol
信息提示
请填处理意见